Quantcast

Latest Eisai Co. Ltd. Stories

2012-09-25 04:20:08

Tokyo, Sept 25, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Santen Pharmaceutical Co., Ltd. announced today that they have entered into an option agreement which grants Santen rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology.Under the terms of the agreement, Eisai shall grant Santen the rights to evaluate the feasibility of developing compounds disclosed by Eisai for use in the ophthalmologic field within a certain period as well as the rights...

2012-09-12 04:20:07

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington D.C., President: Dr. Peter Hotez, "Sabin") with E6020, an in-house developed adjuvant that enhances the immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge, to support the development of vaccines for two neglected tropical diseases (NTDs) - Chagas disease...

2012-09-12 04:20:02

Tokyo, Sept 12, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch Crystal Veil(R) alpha (classified as miscellaneous goods), a drug-free topical nasal gel that utilizes positively charged ions to help block viruses from entering the body through the nose, on Tuesday, September 18.Crystal Veil alpha is a positively-charged gel that helps prevent virus particles, which are even smaller than pollen, from entering through the nose. It is the third product in the Crystal...

2012-09-11 04:20:06

Tokyo, Sept 11, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the anti-rheumatic agent Careram(R) (iguratimod) in Japan on September 12 for the treatment of rheumatoid arthritis. Careram, jointly developed in Japan by Eisai and Toyama Chemical Co., Ltd. from the Phase III clinical development stage, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) in June of this year and was subsequently listed on the National Health Insurance Drug Price...

2012-08-31 08:20:01

Eradication by Concomitant Therapy with Proton Pump Inhibitors, Amoxicillin Hydrate and either Clarithromycin or MetronidazoleTokyo/Osaka, Aug 31, 2012 - (JCN Newswire) - Takeda Pharmaceutical Company Limited (Headquarters: Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Headquarters: Osaka, President: Paul Hudson), Mitsubishi Tanabe Pharma Corporation (Headquarters: Osaka; President: Michihiro Tsuchiya), and Eisai Co., Ltd. (Headquarters: Tokyo; President and CEO: Haruo Naito)...

2012-08-20 00:20:05

Tokyo, Aug 20, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received orphan drug designation from Japan's Ministry of Labour, Health and Welfare for its multikinase inhibitor lenvatinib mesylate ("lenvatinib") for the treatment of thyroid cancer, the drug's prospective indication.Lenvatinib, discovered and being developed in-house, is an anti-angiogenic agent with a unique inhibitory profile against the receptor tyrosine kinase family of kinases. It is a potent...

2012-07-30 04:20:03

Tokyo, July 30, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its research and development subsidiary KAN Research Institute, Inc., currently located within the Kobe Biomedical Innovation Cluster, has received official approval from the city of Kobe to take part in a special international strategic development project being implemented within the Kansai International Strategic Innovation Zone and has therefore decided to relocate to a new research facility within the Zone in...

2012-07-19 04:20:02

Tokyo, July 19, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that the first data from clinical studies with E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor discovered and being developed in-house as a treatment for Alzheimer's disease, were presented during oral sessions at the Alzheimer's Association International Conference (AAIC) 2012.Beta-amyloid (Abeta) deposition in the brain is thought to be one of causes of Alzheimer's disease, and it is...

2012-07-17 12:20:03

- Partnership Based on Open Innovation That Leverages Eisai's Natural Product Chemistry-Based Drug Discovery Platform -Tokyo, July 17, 2012 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a research collaboration with U.S. biopharmaceutical company Verastem, Inc. for the generation of small molecule Wnt inhibitors that target cancer stem cells. Based on this agreement, Eisai will synthesize analogs of VS-507 (salinomycin) with the aim of...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related